|
|
|
17 September 2020
Sally Pipes, President, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute, discusses President Trump’s recent executive order regarding drug pricing, how importing foreign drug price controls could curtail innovation and limit access to the newest drugs, and why the timing of such a policy is wrong amid the ongoing COVID-19 pandemic.
0:00
0:00
Related Podcasts
04 December 2025
Phil Kerpen, President and Founder of American Commitment, discusses the recent drug-pricing deal negotiated by the Trump administration with the United Kingdom, the multiple benefits the agreement will have for Americans and drug innovation, why taxpayer subsidies to health insurers will not lower healthcare costs, and why price controls for credit card transactions are a bad idea.
02 September 2024
Sally Pipes, Founder and President of Pacific Research Institute, discusses the impact of drug price controls under the Inflation Reduction Act (IRA), what it means for research and development of life-saving medicines, and how the IRA's drug pricing provisions will reduce access to new cures and treatments and result in longer wait times for existing medicines.
09 December 2022
Lance Izumi, Senior Director of the Center for Education at the Pacific Research Institute, discusses why student test scores are plunging, how Congress can improve education, and the role teachers' unions and government regulations play in our schools and education systems.
13 October 2022
Sally Pipes, President and CEO of Pacific Research Institute, discusses the likely disastrous effects of drug price control provisions contained in the Inflation Reduction Act and why Congress should embrace a free-market vision when it comes to healthcare by lowering taxes, encouraging innovation and expanding access.
14 August 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at the Center for Individual Freedom, discusses President Trump's executive orders on drug pricing and the negative consequences of government price controls on innovation and to consumers.
03 May 2019
Phil Kerpen, President of American Commitment, discusses prescription drug prices, the fundamental problems with importing foreign price controls, and the steps Congress can take to improve the system.
